The Effects of Beta Blockers on Morbidity and Mortality in Heart Failure
- Syed M. Jafri
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Beta-adrenergic receptor blockers are effective in reducing morbidity and mortality in heart failure. These drugs slow the progression of heart failure by modifying the remodeling process, prevent or delay need for hospital admission for heart failure. They reduce both pump failure and sudden arrhythmic death. There are many patients that do not receive beta blocker therapy in the heart failure population. Patients are often treated with beta blockers not tested in clinical trials to demonstrate efficacy in this patient population. Results from the recently published trials are summarized to emphasize the proper selection and dosage of beta blocker therapy to optimize the care of this high risk population.
- Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-510.
- The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
- Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 1724-1729.
- Cohn JN, Levine TB, Olivari MT, et al. Plasma nore-pinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
- Kao W, Gheorghiade M, Hall V, et al. Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1989; 64: 609-613.
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized In-tervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
- Hjalmarson A, Goldstein S, Fagerberg S, et al. Effects of controlled-release metoprolol on total mortality, hospitalization and well being in patients with heart failure. JAMA 2000; 283: 1295-1302.
- Goldstein S, Kennedy HL, Hall C, et al. Metoprolol CR/XL in patients with heart failure: A pilot study examining tol-erability, safety and effect on left ventricular ejection fraction. Am Heart J 1999; 138: 1158-1165.
- CIBIS Investigators and Committees. A randomized trial of b-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.
- CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet 1999; 353: 9-13.
- Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the Beta-blocker Bucindolol in patients with advanced chronic heart failure. NEngl J Med 2001; 344: 1659-1667.
- Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et al. â-Blockade With Bucindolol In Heart Failure Caused By Ischemic Versus Idiopathic Dilated Cardiomyopathy. Circulation 1991; 84: 2426-2441.
- Packer M, Coats AJ, Fowler MB, et al. Effect of Carvedilol on survival in severe heart failure. N Engl J Med 2001; 344: 1651-1658.
- Poole-Wilson PA, Swedberg K, Cleland JGF, et al. For the COMET Investigators. Comparison of Carvedilol and Metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European Trial (COMET): A randomized controlled trial. LANCET 2003: 362: 7-13.
- The Effects of Beta Blockers on Morbidity and Mortality in Heart Failure
Heart Failure Reviews
Volume 9, Issue 2 , pp 115-121
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- beta blockers
- Industry Sectors
- Syed M. Jafri (1)
- Author Affiliations
- 1. Henry Ford Hospital, Heart & Vascular Institute, Detroit, MI, 48202-2689, USA